Search results
Results from the WOW.Com Content Network
The disease is characterized by slowly progressive weakness and wasting of both proximal muscles (located on or close to the torso) and distal muscles (close to hands or feet), most apparent in the finger flexors and knee extensors. [3] IBM is often confused with an entirely different class of diseases, called hereditary inclusion body ...
Cancer pain treatment aims to relieve pain with minimal adverse treatment effects, allowing the person a good quality of life and level of function and a relatively painless death. [27] Though 80–90 percent of cancer pain can be eliminated or well controlled, nearly half of all people with cancer pain in the developed world and more than 80 ...
CIPN afflicts between 30% and 40% of patients undergoing chemotherapy. Antineoplastic agents in chemotherapy are designed to eliminate rapidly dividing cancer cells, but they can also damage healthy structures, including the peripheral nervous system. [1] CIPN involves various symptoms such as tingling, pain, and numbness in the hands and feet. [2]
Palliative care is appropriate at any stage of multiple myeloma and can be provided alongside curative treatment. In addition to addressing symptoms of cancer, palliative care helps manage unwanted side effects, such as pain and nausea related to treatments. [144] [145]
This removes the legs, the genitalia (internal and external), urinary system, pelvic bones, anus, and rectum. [ 1 ] [ 2 ] It is a major procedure recommended only as a last resort for people with severe and potentially fatal illnesses such as osteomyelitis , tumors , severe traumas and intractable decubiti in, or around, the pelvis . [ 3 ]
The predominant symptoms of NC involve one or both legs and usually presents as some combination of tingling, cramping discomfort, pain, numbness, or weakness in the lower back, calves, glutes, and thighs and is precipitated by walking and prolonged standing. However, the symptoms vary depending on the severity and cause of the condition.
Immunoglobulin and steroids are the first line choices for treatment. [citation needed] In severe cases of CIDP, when second-line immunomodulatory drugs are not efficient, autologous hematopoietic stem cell transplantation (HSCT) is sometimes performed. The treatment may induce long-term remission even in severe treatment-refractory cases of CIDP.
Anderson and colleagues from St Thomas' Hospital, London, were the first to mention a case with possible clinical findings of LEMS in 1953, [11] but Edward H. Lambert, Lee Eaton, and E.D. Rooke at the Mayo Clinic were the first physicians to substantially describe the clinical and electrophysiological findings of the disease in 1956.